In the articles below two contributors discuss recent progress in pathogenesis, management, and diagnosis of some thyroid disorders. Dr. Reginald Hall summarizes the evidence that long-acting thyroid stimulator is an antibody, speculating that after reacting with a thyroid chalone it may trigger off Graves's disease. Dr. R. N. Smith discusses management, and emphasizes that recent progress has concentrated on minimizing the complications of established methods of treatment.
Hyperthyroidism is the clinical condition resulting from an increase in the circulating levels of the thyroid hormones (Lthyroxine or L-triiodothyronine, or both). Normal people given doses of thyroxine above 0-3 to 0.4 mg. per day or 100 to 140 ,ug. daily of triiodothyronine will develop hyperthyroidism, but in the elderly or in those with ischaemic heart disease much lower doses may cause side-effects. Spontaneous hyperthyroidism may be due either to autonomous thyroid overactivity or to the action of stimulating agents on the thyroid. The first cause includes toxic adenoma and toxic multinodular goitre. There are probably two varieties of the latter.' In the first, hyperthyroidism develops in a patient with a pre-existing nodular goitre; eye signs may be present, and histologically the thyroid shows hyperplasia of the paranodular tissue. In the second type one or usually several nodules in a multinodular gland become autonomous and produce excess thyroid hormone.
Excess production of the thyroid-stimulating hormone secreted by the pituitary has never been convincingly shown to cause hyperthyroidism.5 In acromegaly goitres are not infrequent, but the levels of thyroid stimulating hormone (T.S.H.) are not raised and the occasional cases of hyperthyroidism are coincidental. Moreover, if a goitre is present in a patient with acromegaly the hypermetabolism seen in the latter may lead to the erroneous diagnosis of hyperthyroidism. Some trophoblastic tumours do produce a substance resembling thyroid-stimulating hormone, which possibly gives rise to a form of hyperthyroidism,3 though in most cases the evidence for hyperthyroidism has not been very convincing.
Graves's Disease
In the United Kingdom most cases of hyperthyroidism fall into the category of Graves's disease, an eponym best retained to describe a syndrome comprising goitre, hyperthyroidism, eye signs, and, rarely, localized myxoedema and acropachy, though not all of these features are usually present in an individual patient. Both the goitre and hyperthyroidism are now known to be due to the action of a humoral agent acting on the thyroid,4 which because its action is prolonged under laboratory conditions has been designated the long-acting thyroid stimulator (L.A.T.S. reduced-for example, after thyroidectomy or radioiodine therapy and in the presence of thyroiditis.
Further tests for solving difficult problems include estimating the absolute iodine uptake rate24 by the thyroid; the triiodothyronine suppression test25 is helpful in distinguishing those raised thyroid radioiodine uptakes which are caused by iodine deficiency or early autoimmune thyroiditis. If the radioiodine uptake is found to be suppressed, this virtually excludes a diagnosis of hyperthyroidism; nevertheless, failure of suppression is also seen in ophthalmic Graves's disease, in some euthyroid patients with Graves's disease, and in the presence of one or more autonomous nodules in the thyroid. Thyroid antibody tests are also useful since they give a clue to the presence and extent of autoimmune thyroiditis. Subclinical thyroiditis is not infrequent in the general population-high thyroglobulin antibody titres were found in 4-6% of women and 1-6% of men in a general practice in the north-east of England."9 Special Diagnostic Problems During Antithyroid Therapy.-The level of thyroid function during a course of antithyroid drugs is best assessed clinically. Radioiodine uptake measurements 24 hours or more after the tracer dose are not helpful, though those done 20 minutes after intravenous tracer doses of 132I give a measure of thyroid iodide trapping which is independent of drugs.2x Measurements of P.B.I. may be misleadingly low, since the thyroid depleted of iodine produces more triiodothyronine than normal during antithyroid therapy and this is less well bound to thyroxine-binding globulin.
After Antithyroid Therapy. Medical_Journal, 1970, 1, 745-748 Several developments in the management of thyroid disorders have been discussed in recent articles in the British Medical 7ournal-concerning radioiodine therapy,32 antithyroid drug treatment,33 and thyroid hormones.34 To enable him to make the correct choice of treatment and subsequent management of a patient the doctor should be familiar with recent therapeutic studies.
Thyrotoxicosis Antithyroid Drugs
Blocking iodine metabolism in the thyroid gland reduces the output of iodinated thyroid hormones and relieves both the symptoms and some of the signs of thyrotoxicosis. Nevertheless, it is doubtful whether antithyroid drugs alter the underlying mechanism of thyrotoxicosis. Spontaneous remission of thyrotoxicosis does occur,35 and prolonged treatment with anti-thyroid drugs may only control the patient's symptoms until normal thyroid function recovers spontaneously.
Thyrotoxicosis frequently recurs after antithyroid medication, the percentage of recurrences varying from 50 to 70 in different studies, and the relapse can be hastened by iodide repletion.2? The fact that triiodothyronine (T-3) suppresses the uptake of radioiodine (13II) by the thyroid suggests that the autonomous metabolism characteristic of thyrotoxicosis is absent. Moreover, the development of T-3 suppression in a previously thyrotoxic patient while receiving antithyroid drugs may indicate that normal thyroid function has been reestablished.3?
Antithyroid drugs are often used inadequately, the common errors being to allow long intervals between doses or to produce hyperplasia of the thyroid with unduly large doses of these goitrogenic compounds. The metabolism of commonlyused antithyroid drugs, carbimazole and propylthiouracil, differs, and several factors-including renal function-determine their therapeutic efficacy.37 The dosage of these compounds must be adjusted according to the patient's response to therapy, and the doses divided, not according to mealtimes,
